Definium Therapeutics (DFTX) Shares Outstanding (Weighted Average) (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $100.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $100.2 million, up 17.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.2 million (up 17.8% YoY), and the FY2025 annual result was $89.3 million, up 26.78% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $100.2 million in Q1 2026 per DFTX's latest filing, from $4.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $100.2 million in Q1 2026 and troughed at $4.2 million in Q4 2025.
• A 5-year average of $50.2 million and a median of $39.2 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) surged 11495.97% in 2022, then sank 94.04% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $30.9 million in 2022, then rose by 26.9% to $39.2 million in 2023, then jumped by 79.94% to $70.5 million in 2024, then slumped by 94.04% to $4.2 million in 2025, then soared by 2285.9% to $100.2 million in 2026.
• Business Quant data shows DFTX's Shares Outstanding (Weighted Average) at $100.2 million in Q1 2026, $4.2 million in Q4 2025, and $85.9 million in Q3 2025.